Analysis of GRK2 aggregation in the pathology of Alzheimer disease in animal models
- Cell Rep Med. 2026 Apr 21;7(4):102707. doi: 10.1016/j.xcrm.2026.102707.
- 1. Molecular Pharmacology, ETH Zurich, 8057 Zurich, Switzerland.
- 2. Department of Pharmaceutical Sciences, University of Vienna, 1090 Vienna, Austria.
- 3. Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
- 4. Medical Research Center (MRC), Ain Shams University Hospitals, Cairo 11566, Egypt.
- 5. Molecular Pharmacology, ETH Zurich, 8057 Zurich, Switzerland; Institute of Pharmacology and Toxicology, University of Zurich, 8057 Zurich, Switzerland. Electronic address: [email protected].
The G-protein-coupled receptor kinase 2 (GRK2) exerts essential functions in cell growth and survival. Searching for a connection between GRK2 and the neurodegenerative Alzheimer disease (AD), we find increased aggregated serine-670-phosphorylated GRK2 (phospho-S670-GRK2) in brains of AD mice and patients with dementia likely due to AD. Harmful phospho-S670-GRK2 aggregation is induced by two hallmark proteins of AD: beta-amyloid and the neurofibrillary-tangle-inducing, TAU-P301L. Aggregated phospho-S670-GRK2 triggers aggregation of TOMM6 (translocase of outer mitochondrial membrane 6), promotes mitochondrial dysfunction, and enhances beta-amyloid. Transgenic expression of inactive GRK2-K220R or a GRK-inhibitory peptide proves that neuropathological features are caused by GRK2 inactivation. Restoration of TOMM6 by neuron-specific TOMM6 expression reduces beta-amyloid plaques but enhances soluble beta-amyloid and increases mortality. In contrast, reconstitution of monomeric GRK2 and proteasomal phospho-S670-GRK2 degradation by small molecules counteracts neuropathological AD features, prevents neuronal loss, and improves survival. Thus, targeting of pathological GRK2 aggregation slows aging-induced neurodegeneration.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Neurological Disease